Leonabio Inc (LONA)

$5.30 -0.07 (-1.30%)
Market Cap 20.90M
Revenue (ttm) 0.00
Net Income (ttm) -96.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 12,500
Avg Vol 75,556
Day's Range N/A - N/A
Shares Out 3.94M
Stochastic %K 23%
Beta 2.68
Analysts Sell
Price Target $10.00

Company Profile

LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 620 8501
Address:
18706 North Creek Parkway, Suite 104, Bothell, United States
SebNo1234
SebNo1234 Mar. 9 at 12:36 PM
$LONA
0 · Reply
SebNo1234
SebNo1234 Mar. 7 at 6:34 PM
$LONA https://m.aktiencheck.de/news/Nasdaq-LeonaBio_s_Strategic_Pivot_A_New_Identity_for_a_Refocused_Pipeline-19538089
0 · Reply
SebNo1234
SebNo1234 Feb. 26 at 2:20 PM
$LONA https://de.investing.com/news/analyst-ratings/cantor-fitzgerald-startet-coverage-fur-leona-bio-mit-overweight-93CH-3362612
0 · Reply
GoCoogs
GoCoogs Feb. 26 at 1:52 PM
$LONA LeonaBio initiated with an Overweight at Cantor Fitzgerald
0 · Reply
6GodEnergy
6GodEnergy Feb. 25 at 7:51 PM
$LONA $OCUL $MGRX $FIG >3<
0 · Reply
6GodEnergy
6GodEnergy Feb. 24 at 11:34 PM
-@SqueezeSharkie is on another level, clearly ahead of most traders here. If you’re serious about leveling up, you should already be following him. It costs nothing, takes seconds, and the results speak for themselves. { $CBIO $PRLD $NDLS $LONA }
1 · Reply
6GodEnergy
6GodEnergy Feb. 23 at 1:29 PM
$LFS $LONA $CARL $PAAS .’x
0 · Reply
UgoGreg
UgoGreg Feb. 20 at 10:57 PM
$LONA https://youtu.be/DcUGrhgXaKw
0 · Reply
SebNo1234
SebNo1234 Feb. 20 at 10:40 AM
$LONA https://de.investing.com/news/analyst-ratings/mizuho-stuft-leonabio-hoch-aktie-mit-uber-110--kurspotenzial-dank-brustkrebsmedikament-93CH-3350464
0 · Reply
SebNo1234
SebNo1234 Feb. 20 at 10:21 AM
$LONA share price Potential of over 110% thanks to breast cancer https://de.investing.com/news/analyst-ratings/mizuho-stuft-leonabio-hoch-aktie-mit-uber-110--kurspotenzial-dank-brustkrebsmedikament-93CH-3350464
0 · Reply
Latest News on LONA
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

Feb 3, 2026, 7:00 AM EST - 4 weeks ago

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Dec 18, 2025, 2:17 PM EST - 2 months ago

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Dec 18, 2025, 1:47 PM EST - 2 months ago

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Dec 18, 2025, 1:09 PM EST - 2 months ago

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Dec 18, 2025, 7:02 AM EST - 2 months ago

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Athira Pharma Announces Reverse Stock Split

Sep 11, 2025, 9:00 AM EDT - 6 months ago

Athira Pharma Announces Reverse Stock Split

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

May 13, 2025, 11:00 AM EDT - 10 months ago

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

May 9, 2025, 4:05 PM EDT - 10 months ago

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Feb 27, 2025, 4:05 PM EST - 1 year ago

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Jan 7, 2025, 5:15 PM EST - 1 year ago

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Dec 6, 2024, 5:30 PM EST - 1 year ago

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Sep 17, 2024, 11:59 AM EDT - 1 year ago

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Sep 17, 2024, 9:00 AM EDT - 1 year ago

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Sep 4, 2024, 8:48 AM EDT - 1 year ago

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Sep 3, 2024, 4:13 PM EDT - 1 year ago

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Jul 31, 2024, 8:05 AM EDT - 1 year ago

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Athira Pharma to Participate in Upcoming June Conferences

May 29, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

May 17, 2024, 5:00 PM EDT - 1 year ago

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 15, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma to Participate in Upcoming May Conferences

May 2, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Mar 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Feb 22, 2024, 4:05 PM EST - 2 years ago

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Feb 8, 2024, 4:02 PM EST - 2 years ago

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Jan 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Jan 3, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Dec 12, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Nov 29, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Nov 15, 2023, 8:15 AM EST - 2 years ago

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Athira Pharma to Participate in Jefferies London Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Jefferies London Healthcare Conference

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Oct 5, 2023, 4:30 PM EDT - 2 years ago

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Jul 17, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

Jul 6, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

May 22, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

Athira Pharma to Participate in Upcoming May Investor Conferences

May 8, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma to Participate in Upcoming May Investor Conferences

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 25, 2023, 4:01 PM EDT - 3 years ago

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 11, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Mar 28, 2023, 1:00 AM EDT - 3 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Mar 23, 2023, 4:05 PM EDT - 3 years ago

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

Mar 6, 2023, 7:00 AM EST - 3 years ago

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

Feb 1, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Jan 31, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

SebNo1234
SebNo1234 Mar. 9 at 12:36 PM
$LONA
0 · Reply
SebNo1234
SebNo1234 Mar. 7 at 6:34 PM
$LONA https://m.aktiencheck.de/news/Nasdaq-LeonaBio_s_Strategic_Pivot_A_New_Identity_for_a_Refocused_Pipeline-19538089
0 · Reply
SebNo1234
SebNo1234 Feb. 26 at 2:20 PM
$LONA https://de.investing.com/news/analyst-ratings/cantor-fitzgerald-startet-coverage-fur-leona-bio-mit-overweight-93CH-3362612
0 · Reply
GoCoogs
GoCoogs Feb. 26 at 1:52 PM
$LONA LeonaBio initiated with an Overweight at Cantor Fitzgerald
0 · Reply
6GodEnergy
6GodEnergy Feb. 25 at 7:51 PM
$LONA $OCUL $MGRX $FIG >3<
0 · Reply
6GodEnergy
6GodEnergy Feb. 24 at 11:34 PM
-@SqueezeSharkie is on another level, clearly ahead of most traders here. If you’re serious about leveling up, you should already be following him. It costs nothing, takes seconds, and the results speak for themselves. { $CBIO $PRLD $NDLS $LONA }
1 · Reply
6GodEnergy
6GodEnergy Feb. 23 at 1:29 PM
$LFS $LONA $CARL $PAAS .’x
0 · Reply
UgoGreg
UgoGreg Feb. 20 at 10:57 PM
$LONA https://youtu.be/DcUGrhgXaKw
0 · Reply
SebNo1234
SebNo1234 Feb. 20 at 10:40 AM
$LONA https://de.investing.com/news/analyst-ratings/mizuho-stuft-leonabio-hoch-aktie-mit-uber-110--kurspotenzial-dank-brustkrebsmedikament-93CH-3350464
0 · Reply
SebNo1234
SebNo1234 Feb. 20 at 10:21 AM
$LONA share price Potential of over 110% thanks to breast cancer https://de.investing.com/news/analyst-ratings/mizuho-stuft-leonabio-hoch-aktie-mit-uber-110--kurspotenzial-dank-brustkrebsmedikament-93CH-3350464
0 · Reply
SebaNovak
SebaNovak Feb. 19 at 8:28 PM
$LONA thin micro conditions and if volume appears expect quick movement
0 · Reply
6GodEnergy
6GodEnergy Feb. 19 at 7:22 PM
$NBY $LONA $FLUX $HLF ~~
0 · Reply
SebNo1234
SebNo1234 Feb. 19 at 6:56 PM
$LONA
0 · Reply
SebNo1234
SebNo1234 Feb. 19 at 5:12 PM
$LONA
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 2:44 PM
$LONA RSI: 54.62, MACD: -0.3112 Vol: 0.46, MA20: 4.89, MA50: 5.62 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 3:48 AM
$LONA RSI: 48.09, MACD: -0.3507 Vol: 0.55, MA20: 4.96, MA50: 5.60 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SebNo1234
SebNo1234 Feb. 18 at 9:47 PM
$LONA
0 · Reply
InstitutionalAllocator
InstitutionalAllocator Feb. 17 at 12:30 PM
$LONA Obscure micro-cap; likely illiquid with no coverage.
0 · Reply
OptionField
OptionField Feb. 9 at 2:19 PM
$LONA Consumer brand; building national awareness requires significant capital.
0 · Reply
BioTuesdays
BioTuesdays Feb. 3 at 4:22 PM
$LONA has appointed Mark F. Kubic as chief business officer (CBO) to lead the company’s business development strategy and execution https://biotuesdays.com/2026/02/03/leonabio-appoints-industry-veteran-mark-f-kubic-as-cbo/
0 · Reply
SebNo1234
SebNo1234 Jan. 30 at 3:04 PM
$LONA I hope of good news soon!🍀🤞🚀🍀🤞
0 · Reply
Alyssa_CC
Alyssa_CC Jan. 15 at 7:02 PM
@Pfreakstocks @howardlindzon Thanks for flagging! $LONA has been created and $ATHA messages etc is being transferred over to the new ticker!
0 · Reply